Recommendation of the President – Columvi (glofitamab)
On 31 October 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 157/2025 on the reimbursement of the medicinal product Columvi (glofitamab) under the drug program “Treatment of patients with B-cell lymphomas (ICD-10: C82, C83, C85)”